Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Limertinib - Jiangsu Aosaikang Pharmaceutical

Next Previous
Drug Profile

Limertinib - Jiangsu Aosaikang Pharmaceutical

Alternative Names: Aoyixin; ASK 120067

Latest Information Update: 07 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Aosaikang Pharmaceutical
  • Developer Innovent Biologics; Jiangsu Aosaikang Pharmaceutical
  • Class Amides; Anilides; Aniline compounds; Anisoles; Antineoplastics; Aromatic hydrocarbons; Chlorinated hydrocarbons; Ethylenediamines; Naphthalenes; Pyrimidines; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 23 Dec 2025 Limertinib is still in phase I trials for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in China (PO, tablet) (NCT05306132)
  • 17 Oct 2025 Adverse event and efficacy data from a phase I trial in Solid tumours cancer presented at the 50th European Society for Medical Oncology Congress (ESMO 2025)
  • 28 Sep 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in China (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top